The impact of mutation of myelodysplasia-related genes in de novo acute myeloid leukemia carrying npm1 mutation “2279

HIGHLIGHTS

SUMMARY

While cases with concurrent FLT3-ITDhigh (allelic ratio (AR) > 0.5) were previously designated as "intermediate-risk" based on the European LeukemiaNet (ELN) risk stratification, the newly updated ELN classification now categorizes all cases with NPM1-mutated AML with FLT3-ITD co-mutation as intermediate-risk group regardless of AR. Historically, patients who developed AML preceded by a history of myelodysplastic syndrome (MDS) or with cytogenetic aberrations associated with MDS (-7/7q-, complex, etc.) were designated as AML with myelodysplasia-related changes (AML-MRC) rather than AML with NPM1 mutation even if the mutation . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.